Physician profile
Avidon Appel
NPI 1770650723
$10,271.65
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.12 · 2020: $44.01 · 2021: $3,595 · 2022: $5,043 · 2023: $1,253 · 2024: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,415 · Food and Beverage: $76.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,415.44 |
| Food and Beverage | $76.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $8,573.74 | 2021-2022 | |
| Abbvie INC. | $1,415.44 | 2023-2024 | |
| Galderma Laboratories, L.P. | $76.33 | 2024 | |
| Novo Nordisk INC | $71.30 | 2019-2020 | |
| Horizon Therapeutics Plc | $26.10 | 2022 | |
| Pfizer INC. | $21.65 | 2021 | |
| Scilex Pharmaceuticals INC. | $20.90 | 2019 | |
| Gilead Sciences, INC. | $19.43 | 2019 | |
| Currax Pharmaceuticals LLC | $17.26 | 2022 | |
| Lilly USA, LLC | $16.12 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.38 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avidon Appel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.